Introduction
A 'thrombin-like' activity, first identified by chromogenic assays in some prothrombin complex concentrates, may be associated with a 65 -70 kDa protein of unusual chromatographic behaviour . This enzyme was termed plasma hyaluronan binding serine protease (PHBSP) because it represented the functional enzyme of a truncated, catalytically inactive plasma hyaluronan-binding protein (Choi-Miura et al., 1996) . A serine protease identical to PHBSP has recently been reported to activate plasminogen activators (Römisch et al., 2000) and FVII in a tissue factor-independent way (Römisch et al., 1999) . Furthermore, in vitro-data showed that FV and FVIII are inactivated by this protease (Römisch et al., 1999 , and our own unpublished observation). Therefore, a pro-and anticoagulatory, as well as a profibrinolytic potency is attributed to PHBSP. For all these functions, however, a physiological relevance remains to be shown.
PHBSP is a trypsin-like protease consisting of 537 amino acids in its mature proenzyme form (Choi-Miura et al., 1996) . In the N-terminal part (propeptide or 'activation segment'; Khan and James, 1998 ) three epidermal growth factor-like and one kringle domain are present, in the C-terminal part the catalytic triade is found. A total concentration of 12 µg/ml (200 nM) PHBSP in plasma was determined by quantitative ELISA (Römisch et al., 2001) . The proenzyme undergoes an intermolecular autocatalytic activation by cleavage at an internal Arg 290 -Ile bond (Etscheid et al., 2000) resulting in an N-terminal 48 kDa heavy chain and a C-terminal 30 kDa light chain held together by a single disulfide bond. PHBSP activity and proenzyme activation in vitro are effectively inhibited by plasma serpins, especially α 2 -antiplasmin and C1-esterase inhibitor.
The single-chain plasminogen activator-activating potency and the strong inhibition of PHBSP by C1-esterase inhibitor Römisch et al., 2000) indicated catalytic similarities between PHBSP and the contact phase enzyme plasma kallikrein (PK). Very little is known about the interaction of PHBSP with components of the contact activation system (plasma kallikrein/kinin(PPK, Fletcher factor) and the coagulation factor XII (FXII, Hageman factor). Within the intrinsic coagulation cascade, the coagulation factor XI (FXI) is closely associated with the contact activation system (Donaldson et al., 1976; Cochrane and Griffin, 1979; Kaplan, 1979) . C1 esterase inhibitor is considered as the major regulator of the surface-mediated contact phase system (Cameron et al., 1989; Colman, 2001) .
HK is a single chain glycoprotein of 120 kDa, composed of 626 amino acids, comprising the domains D1-D4, D5 H and D6 H . In plasma HK is mostly found in complex with PK or FXI, mediated by domain D6 (Mandle et al., 1976; Thompson et al., 1977) . The activated forms of both zymogens, plasma kallikrein (PK) and FXIa, can cleave the pro-cofactor HK to finally release the vasoactive peptide bradykinin (BK), although the cleavage patterns differ (Scott et al., 1985; Mauron et al., 2000) . Unlike FXIa, BK release by plasma kallikrein leaves behind activated kininogen (HKa) which has anti-adhesive and antiangiogenic functions (Colman, 2001) . Low molecular weight kininogen (LK) is a 66 kDa single chain glycoprotein representing a splicing variant transcribed from the same single-copy gene as HK, yielding identical domains D1 to D4. The procoagulatory PK-and FXI-binding domain D6 H is missing in LK, and domain D5 L is only 4 kDa in length and its amino acid sequence is unrelated to D5 H of HK (Takagaki et al., 1985) . FXI and PPK are structurally related proteins sharing 58% amino acid sequence identity (De La Cadena et al., 1994) . The binding regions for HK have been mapped to apple domains A1, A2, and A4 of PK (Page et al., 1994; Renné et al., 1999) and A1, A2, and A4 of FXI (Baglia et al., 1990; Renné et al., 2002) , respectively. PK consists of an N-terminal heavy chain of 52 kDa that is disulfide-linked to two light chain variants (36 or 33 kDa). This PK, designated α-kallikrein (PKα), can catalyze an autolytic cleavage within the second apple domain generating β-kallikrein (PKβ), which has a similar FXII-activating potency but a diminished rate of cleavage of HK (Colman et al., 1985) .
Here we demonstrate that the hyaluronan-binding serine protease from human plasma represents a novel kininogen-cleaving enzyme, and we show that also in plasma the vasoactive nonapeptide bradykinin is released from kininogen. The cleavage mechanism is compared to that of other kininogen processing plasma enzymes. We further investigated whether besides high molecular weight also low molecular weight kininogen could function as a substrate for PHBSP and whether glycosoaminoglycans (GAGs) affect kininogen cleavage by PHBSP. The physiological relevance of the findings is discussed.
Results

Proenzymes of the Contact Activation System
In order to evaluate the influence of PHBSP on the contact activation system the purified proenzymes of this system were incubated with PHBSP. When commercially available preparations of PPK, FXI and FXII (each at a final concentration of 2.8 µM) were treated with 78 nm PHBSP no cleavage products could be observed by SDS-PAGE ( Figure 1A ). Also at equimolar ratio no cleavage was detectable (not shown) indicating that none of these proenzymes is a substrate of PHBSP. From these results it was concluded that PHBSP does not directly participate in the regulation of the enzymes of the contact activation system. Lanes 3, 6, and 9 show PK, FXIa and FXIIa for comparison. The lack of a visible heavy chain of 52 kDa in the commercial PK preparation (lane 3) indicated that it is apparently not the α-form but mostly the β-form, presumably as result of autolproteolytic cleavage during preparation or storage. A strongly reduced HKbinding potency of the PK β used in this study compared to an equal amount of PPK was found in a ligand-binding assay (Figure 2 ). In the same assay PHBSP exhibited only a very weak affinity for HK. Thus, the lack of both enzymes to bind to HK allowed to compare only their catalytic activities, independent of the strong complex formation between PK α and HK.
Cleavage of HMW Kininogen in Solution
When the procofactor HMW kininogen (HK) was incubated with PHBSP under identical conditions as described for the zymogens of the kallikein/kinin system, the reduction of the 120 kDa procofactor band and the generation of two bands of approximately 62 and 47 kDa was observed, generating a cleavage pattern indistinguishable from that obtained with plasma kallikrein ( Figure 1C ). From here we started a more detailed study of the HKcleaving property of PHBSP in comparison to the welldescribed HK-processing enzymes, PK and the coagulation factors FXIa and FXIIa.
In a time course the cleavage of purified procofactor HK by these enzymes in the absence of a surface reactant was analyzed side-by-side. The reaction products were subjected to reducing SDS-PAGE and Western blot analysis with a HK-specific polyclonal antibody. The incubation of HK with PKβ or PHBSP ( Figure 3A , C) resulted in the disappearance of the 120 kDa procofactor band and in the generation of a ~62 kDa band doublet, presumably the heavy chain and a slightly faster migrating intermediate of the light chain. Both enzymes further processed the intermediate, concomitant with the appearance of a ~47 kDa band, the expected mature light chain of activated HK (HKa). The PHBSP-mediated cleavage products, including the intermediate, were similar in size to the products generated by cleavage of HK with plasma kallikrein.
PHBSP (and PKβ) showed a different cleavage pattern compared to FXIa. The treatment of HK with FXIa showed the generation of a ~62 kDa heavy chain. The intermediate of the light chain was not visible ( Figure 3B ). The incubation of HK with FXIa for more than 1 h resulted in the disappearance of the mature light chain, presumably by further cleavage at Lys 502 -Thr 503 removing both surface binding regions from the light chain as reported earlier (Scott et al., 1985; Mauron et al., 2000) . This cleavage step was not observed with PHBSP or PKβ. From the data presented above it was concluded that PHBSP Cleavage of Kininogen by PHBSP 1635 cleaves HK in a similar way as PK but clearly different from FXIa.
FXIIa, structurally related to PHBSP, has been reported to cleave HK in prekallikrein-deficient plasma in the presence, but not in the absence of kaolin to yield cleavage products very similar to those generated by PK (Wiggins, 1983) . Our studies revealed that in the absence of kaolin FXIIa did not cleave HK (data not shown). In contrast, cleavage of HK by PHBSP was not dependent on activating surfaces and was therefore clearly different to the activation of HK by FXIIa. 
Cleavage Sites on HK
Additional Cleavage of the Light Chain of HK
During incubation of HK for several hours with PHBSP the mobility of the light chain increased, best seen in the sample after 4 h incubation (compare Figure 3A and C, blow-up). In order to identify additional cleavage site(s), 15 µg HK were treated for 4 h with PHBSP or PK and was subsequently separated on a 10 -20% SDS-PAGE for low molecular weight proteins. Repeatedly two fragments of approximately 7 kDa became visible ( Figure 3D ) which were not present upon 4 h treatment of HK with PKβ. Partial amino acid sequence analysis revealed that the N-termini of both 7 kDa fragments, KHNLG, were identical, representing the N-terminus of the mature light chain of HK. The location of the additional PHBSP-cleavage site(s) have still to be determined. A size of 7 kDa would correspond to approx. 60 amino acid residue peptides, hence reaching from Lys 420 to a lysine-and histidine-rich domain at Lys 480 within the second surface binding region of the D5 H domain (De La Cadena et al., 1994) .
Release of Kinin
In a radioimmunoassay with bradykinin-specific antibodies the completeness and the rate of the kinin release by PHBSP and PKβ was compared. Additionally, in this experiment it was investigated whether low molecular weight kininogen (LK) can function as substrate for PHB-SP or plasma kallikrein. From master incubation mixtures of HK or LK with PHBSP or PKβ aliquots were withdrawn at specific time points, ethanol-precipitated to remove the high molecular weight proteins, and the concentration of free kinin in the vacuum-dried ethanol supernatant was determined (Figure 4) . In each aliquot withdrawn from the reaction mixture 27 pmol kininogen were present. The cleavage of HK by PHBSP released ~20 pmol kinin (~80%) within 60 min, a complete release of kinin was observed after 120 min. PK completely released the kinin after 15 min already. The time course showed that with identical substrate to enzyme ratios (35:1) the release of kinin by PK occured at a much faster rate compared to PHBSP.
Low molecular weight kininogen (LK) showed repeatedly a slightly faster mobility upon treatment with PHBSP or PK β in PAGE and immunoblot analysis (not shown). To further substantiate these observations, LK was included in the kinin release experiments. The results of the radioimmunoassay demonstrated that both, PHBSP and PK β could process LK to release kinin. In contrast to HK, in the rate of kinin release from LK no significant difference between PK and PHBSP was detectable. The lack of the PK-binding D6 H domain in LK did not prevent cleavage of LK by PKβ. Only the rate and completeness of cleavage was affected. Whether the use of soley PK α compared to PK β would result in a more pronounced difference in the rate of cleavage of HK and LK has not been determined during his study. In summary, the identical LK hydrolysis rate of both enzymes, PHBSP and PKβ, further supports the assumption that they have very similar catalytic properties.
Identity of the Kinin
The results of the radioimmunoassay confirmed the release of kinin from HK or LK. However, whether it was the nonapeptide bradykinin, the decapeptide kallidin (Lys-bradykinin) or smaller BK-metabolites could not be clearly answered because the anti-BK antibody used for detection did not discriminate between these kinin forms. Using MALDI-TOF mass spectrometry, in the ethanol supernatant of PHBSP-treated HK a peak corresponding to 1060.69 was detected, confirming that bradykinin (NH 2 -Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-COOH; M r =1060.22) was generated ( Figure 5A ). Another signal of 904.50 might represent desArg-BK. A peak of 1076.72 corresponds to the mass of BK with an additional hydroxyl group, most likely at the C4 of the proline located on the amino side of a glycine, yielding [Hyp 3 ]-BK (M r =1076.2; Sasaguri et al., 1988) . All the BK-related peaks were also observed when PKβ was used as enzyme ( Figure 5B ), once more confirming the catalytic similarity betweeen PK and PHBSP. Two possibilities describe the origin of the desArg-BK peak. It could result from partial hydrolysis of the Arg 263 -Pro 264 bond in HK instead of the Lys 362 -Arg 363 bond in the second cleavage step of HK processing, thus liberating desArg1-BK. One hour treatment of synthetic bradykinin with PHBSP or PKβ, however, did not result in the removal of Arg1 from BK as determined by MALDI-TOF mass spectrometry (not shown). Another possibility would be that BK is partially metabolized by traces of kininase I (carboxypeptidase N) removing the C-terminal arginine residue and generating desArg9-BK (Murphey et al., 2000) . As expected, the cleavage of LK by PHBSP or PKβ also resulted in the release of BK as determined by MALDI-TOF mass spetrometry (data not shown).
Influence of GAGs on Kininogen Cleavage
The affinity of PHBSP to hyaluronic acid and glycosoaminoglycans (GAGs) like heparin and the function of proteoglycans containing heparan sulfate or chondroitin sulfate (HS and CS) as cell surface receptors for HK (Renné et al., 2000; Renné and Müller-Esterl, 2001 ) raised the question whether kininogen cleavage may be promoted Cleavage of Kininogen by PHBSP 1637 Ten µl freshly donated and citrated plasma was inubated for 90 min with one µl of PHBSP in a final concentration as indicated below each lane. The plasma samples were separated by SDS-PAGE under reducing conditions and were transferred to a PVDF membrane. HK and the BK moiety were immunodetected with (A) an anti-HK polyclonal antibody (α-HK pAb), or (B) an anti-BK polyclonal antibody (α-BK pAb). In the 120 kDa pro-cofactor (HK) the BK moiety was not immunodetectable, but was detectable in cleaved kininogen (HKa). LMW kininogen (66 kDa) comigrated with serum albumin and was not detectable by immunoblot under the chosen conditions. by GAGs. When HK cleavage was studied as function of HS, CS or unfractionated heparin a concentration-dependent increase of kininogen cleavage was found by PAGE and Western blot (Figure 6 ). At >1 mg/ml CS, 0.5 -2 mg/ml HS or 0.025 -0.25 mg/ml heparin (~5 -47 IU/ml) a maximum of HK cleavage was found, indicating that an optimum concentration of these charged molecules facilitate cleavage of HK by PHBSP. The effect of CS was less pronounced compared to HS or heparin. Interestingly, in an earlier study a maximum of autocatalytic activation of proPHBSP was found at a heparin concentration of 5 -10 IU/ml with an approximately 6-fold increase in activation (Etscheid et al., 2000) . This implicates that at a similar optimum concentration of charged GAGs like heparin two important physiologic processes would be promoted, autoactivation of the zymogen and cleavage of a natural substrate. Whether the in vitro effects of HS, CS and heparin are of biological importance, e.g. on the surface of endothelial or other cells, deserves further investigations.
Cleavage of HK in Human Plasma
The in vitro findings presented above indicated that HK is processed by PHBSP in solution to finally liberate bradykinin and activated cofactor, HKa. Consequently we addressed the question whether HK, circulating in plasma in complex with PK or FXI, could be a substrate for PHBSP. When citrated pool plasma was incubated for 90 min with increasing concentrations of purified PHBSP (31.25 nM-4 µM), significant cleavage of HK could be observed only at rather high PHBSP concentrations of 2 µM or above ( Figure 7A ). At 4 µM PHBSP an almost complete processing of HK was detected. Using a BK-specific antibody ( Figure 7B ) it was observed that upon cleavage of HK a 62 kDa band was generated, presumably the heavy chain with the BK moiety attached to its C-terminus. This occured already at PHBSP concentrations below the plasma concentration of proPHBSP (200 nM). An additional BK-specific ~75 kDa band (asterisk in Figure 7B ) was also found upon incubation of plasma with purified PKβ, the identity of this band is still unclear. Our data clearly demonstrate that PHBSP has the potency to cleave the contact phase procofactor HK present in plasma, albeit quantitatively only at elevated, non-physiologic concentrations and prolonged incubation. Whether LK, circulating in plasma at a concentration of 1.3 µM, is also cleaved by PHBSP has not been determined during this study.
Next, the cleavage of HK in plasma was studied time- resolved at a fixed concentration of PHBSP (3 µM). Soybean trypsin inhibitor and the ACE inhibitor captopril were present at 1 µM and 10 mM, respectively, to inhibit PK and to prevent metabolization of BK by angiotensin converting enzyme (ACE). Upon addition of PHBSP the procofactor band disappeared instantly concomitant with the generation of the 62 kDa BK signal ( Figure 8A ) and free kinin ( Figure 8B) . A complete release of BK from the kininogen heavy chain was not observed. Under the chosen conditions PHBSP was able to release 100 nM kinin within the first min of incubation. At prolonged incubation, however, a total of ~240 nM kinin were released. Based on the total concentration of HK + LK in plasma, 2 µM, PHBSP completely processed >10% of plasma kininogens.
Finally we determined by MALDI-TOF mass spectrometry which BK metabolites could be found. Comparing plasma incubated for 60 min at RT in the absence or presence of PHBSP ( Figure 8C ) showed clearly the generation of peaks corresponding to BK (M r =1060.60), desArg-BK (M r =904.53), [Hyp 3 ]-BK (M r =1076.60) and a peak identical to BK1 -7 (M r =757.51) all of which were not visible in the PHBSP-free control. The generation of small BK metabolites BK1 -7 and BK1 -8 (desArg-BK) could be expected because in plasma BK has a rapid turnover with a half life of only 17 s (Murphey et al., 2000) . In summary, our data unequivocally demonstrate that PHBSP cleaves HK (and presumably LK) in plasma and generates the vasoactive peptide bradykinin.
Discussion
The results of our study demonstrate that PHBSP has the potency to activate high and low molecular weight kininogen in vitro. The predominant products of cleavage of HK by PHBSP (Figure 9 ) are comparable to those generated by plasma kallikrein. Additionally we found that both, PHBSP and PKβ, can use LK as substrate releasing BK and cleaved LK with the small light chain remaining attached to the heavy chain of LK by a disulfide bridge. Treatment of HK with PHBSP for prolonged time partially lead to further cleavage of the light chain in domain D5 H , removing at least the first surface and cell binding region from HKa. Unlike PK and PHBSP, FXIa inactivates the cofactor by removing both surface binding regions from the light chain, hence separating the D5 H from the D6 H domain and thus abolishing the procoagulatory function of HKa (Scott et al., 1985; Mauron et al., 2000) . The removal of only the N-terminal part of the surface binding domain D5 H by PHBSP might be involved in the regulation of HK functions at cell surfaces where interactions with peptides up to Lys 480 are required, e.g. in proliferation and migration of endothelial cells or in the binding of HK to neutrophils .
When PHBSP was added to human plasma an almost complete cleavage of HK was observed, including the dominant fraction of HK that circulates in plasma in complex with prekallikrein or FXI. Apparently, prekallikrein and FXI bound to HK do not affect cleavage of HK by PHBSP. The data presented here suggest that cleavage of HK in plasma by physiological concentrations of PHB-SP (proPHBSP = 200 nM) is unlikely to release significant amounts of BK. At sites of increased (pro)enzyme and reduced inhibitor concentrations, however, e.g. at GAGs on cell surfaces or in the perivascular environment, the situation would presumably be different. The propensity of PHBSP to bind to GAGs like hyaluronic acid (Choi-Miura et al., 1996) , the major component of the extracellular matrix (Laurent and Fraser, 1992) or to heparin, raises the possibility that autoactivation of the zymogen and kininogen cleavage with concomitant BK release could be directed to cell surfaces or to the extravascular environment. Although BK release by PHBSP in solution was less complete compared to PKβ, the amount of BK released would presumably be sufficient to produce a local effect, e.g. on cell surfaces. In plasma HK and LK are present at concentrations of 0.66 µM and 1.3 µM, respectively, and >100 nM free kinin were found within 1 min of incubation of plasma with PHBSP. Already 3 nM BK, however, can be sufficient to stimulate cellular responses (Busse and Lamontagne, 1991) . Furthermore, cultured human umbilical vein endothelial cells (HUVECs) can exCleavage of Kininogen by PHBSP 1639 The single-chain precursors HK and LK as well as the products generated by PHBSP are shown. HK and LK are transcribed from the same single copy gene as unique mRNAs by alternative splicing (Takagaki et al., 1985) . The structure and characteristics of the domains are shown as described recently Colman, 2001 ). The termini generated by PHBSP are indicated. The fragment released from the D5 H domain of HKa by prolonged incubation with PHBSP is shown with dotted lines. Upon cleavage of LK (LKc) bradykinin is released, while the domain D5 L remains attached to the heavy chain of LMW kininogen by a single disulfide bridge (Kellermann et al., 1987) .
press HK on their surface at a concentration of approximately 9×10 3 HK molecules/cell (Schmaier et al., 1988) , and express 1×10 7 HK binding sites/cell (Zhao et al., 2001) , thus locally increasing the concentration of HK on cell surfaces. Two GAGs, heparan sulfate and chondroitin sulfate have been described as cell surface receptors of kininogen (Renné et al., 2000; Renné and Müller-Esterl, 2001) , and in this study they promoted HK cleavage by PHBSP in vitro. Therefore a locally elevated concentration of HSPGs or CSPGs might promote HK activation by PHBSP.
The ability of PHBSP and PK to activate both, kininogens and prourokinase (sc-uPA) (Römisch et al., 2000) , indicates that PHBSP has an overlapping substrate specificity with PK. Cleavage of FXII, which is a substrate of PK, was not observed for PHBSP. In contrast, activation of FVII and inactivation of FVIII or FV were found for PHBSP (Römisch et al., 1999) but not for PK, indicating that they do not share all enzymatic activities.
The heavy chain of PHBSP consists of three epidermal growth factor-like domains and one kringle domain, whereas the heavy chain of PK possesses four apple domains, three of which are involved in HK-binding (Page et al., 1994; Renné et al., 1999) . Binding experiments showed that PHBSP has only a weak or no affinity to HK. In plasma proPHBSP most likely does not form stable complexes with HK, whereas PPK and FXI are found predominantly associated with HK (Mandle et al., 1976; Thompson et al., 1977) . Through this interaction substrate and proenzyme are in close proximity, facilitating activation of the plasma kallikrein/kinin system, e.g. on endothelial cells (Rojkjaer and Schmaier, 1999) . The structural differences in the heavy chain may direct the function of PK and PHBSP to different locations, where they exhibit similar activities.
It can be hypothesized that HK expressed on endothelial cells or bound to cell matrix (Colman et al., 1985) rather than HK circulating in blood in complex with PPK or FXI would be a substrate for PHBSP. BK liberated from bound HK could stimulate its endothelial cell receptor B 2 to trigger subsequent intracellular reactions like the release of intracellular Ca 2+ (Busse and Fleming, 1996) . Indeed, recent studies demonstrated the PHBSP-mediated release of Ca 2+ from endogeneous stores in cultured HUVECs, a process that was dependent on the proteolytic activity of PHBSP. Interaction with the protease-activated receptors PAR 1 -4 could be excluded during this study (Storck et al., 1999) . Since HK and HK receptors are synthesized in cultured endothelial cells and are expressed on the cell surface (Schmaier et al., 1988 ) the PHBSP-dependent Ca 2+ release in HUVECs might be attributed to the liberation of BK from cell-or matrix-bound HK. Further experiments are required to support this hypothesis.
While scuPA is autocatalytically inactive and does not cleave HK, it can be speculated that surface-bound proPHBSP autoactivates and promotes HK or sc-uPA activation and thus initiates subsequent reactions: (i) promoting the binding of HK to cell surface receptors.
On endothelial cells HKa, but not HK can bind to domain 2 and 3 of the urokinase receptor (uPAR) in a zincdependent reaction. The generation of HKa and binding of HKa to uPAR are initial steps in cell adhesion, proliferation and angiogenesis (Chavakis et al., 2000; Colman et al., 2000; Sheng et al., 2000) . (ii) Activation of surface-bound sc-uPA. This would result in plasmin generation on the cell surface, initiating cellassociated fibrinolysis.
The surface-bound plasminogen activator-plasmin system plays a pivotal role in the proteolytic cascade resulting in the activation of matrix metalloproteases, matrix degradation and tissue remodeling (Saksela and Rifkin, 1988; Mignatti and Rifkin, 1996) . Further investigations are required to elucidate the in vivo importance of the HKand scuPA-activating potency of PHBSP in processes like fibrinolysis, angiogenesis, inflammation or blood pressure regulation.
Materials and Methods
Proteins and Antisera PHBSP was prepared as described recently . The goat polyclonal antibody to kininogen was obtained from ICN (Eschwege, Germany), the rabbit polyclonal antibradykinin antibody used in Western blots was from Affiland (Ans-Liege, Belgium), horseradish peroxidase-conjugated secondary antibodies were from Sigma (Deisenhofen, Germany). The kininogens and all proenzymes and enzymes were purchased from Calbiochem (Bad Soden, Germany) unless stated otherwise.
Gel Electrophoresis and Western Blot Analysis
Samples were separated by SDS-PAGE according to Laemmli (1970) and proteins were visualized by Coomassie Brilliant Blue staining of the gel. For Western blot analyses of HK processing, 100 ng HK were loaded to the gel and were transferred to a PVDF membrane (Millipore, Eschborn, Germany). HK and its processing products were visualized by immunodetection using a kininogen-or a bradykinin-specific antibody. After incubation with secondary antibodies the labeled proteins were detected with the chemiluminescent substrate ECL (Amersham-Pharmacia, Freiburg, Germany).
Amino Acid Sequence Analysis
After complete cleavage, 15 µg HK was equally distributed into 3 lanes of a 5 -20% Laemmli gel and separated under reducing conditions. The protein was transferred to a PVDF membrane and the protein bands were visualized by Coomassie Brilliant Blue staining. The N-terminal amino acid sequence was determined by Edman degradation on an Applied Biosystems Procise Sequencer as described earlier .
Cleavage Reactions
HMW and LMW kininogen (2.7 µM each), respectively, were incubated at room temperature with 78 nm of enzyme in cleavage buffer (50 mM Tris-HCl, 150 mM sodium chloride, 10 mM calci-um chloride and 0.1% Tween 20, pH 7.8). For gel analysis identical volumes were withdrawn at the specified time points and were immediately added to 1/3 vol gel loading buffer (1% SDS, 2% mercaptoethanol, 0.02% bromophenol, 10% glycerol) and boiled for 5 minutes. Samples were subjected to SDS-PAGE and Western blot analysis. The cleavage of HK was also studied as function of the GAGs heparan sulfate, chondroitin sulfate, and heparin at identical enzyme to substrate ratio as described above. The reaction proceeded for 10 min at room temperature. The reaction was stopped by adding 1/3 vol. gel loading buffer, and 60 ng HK was subjected to PAGE and immunoblot analysis.
Radioimmunoassay
Incubation of HK or LK with PHBSP or PKβ was performed as described above. At each time point 10 µl (corresponding to 27 pmol HK) were withdrawn and added to 40 µl of a stop solution (50 mM Tris-HCl, 150 mM NaCl, 40 mM EDTA, 4 mM orthophenanthroline, pH 7.8). Immediately, this solution was added to 950 µl 96% ethanol, incubated at 70°C for 10 min, followed by rapid cooling on ice and sedimentation for 5 min at 12 000 g at 4°C in a Heraeus Biofuge (Hanau, Germany). The pellet was reextracted with 96% ethanol and treated as above, and the combined supernatants were evaporated in a speed vac (Eppendorf, Hamburg, Germany). The amount of kinin present in the supernatant was determined by radioimmunoassay as described in Fink et al.(1985) .
Mass Spectrometric Analysis
The kinin-containing fraction of the samples was obtained as described above. The masses of peptides in the evaporated supernatant were determined by matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry in a 3,5-dimethoxy-4-hydroxycinnamic acid matrix on a BIFLEX III system (Bruker Saxonia Analytik, Leipzig, Germany) using the reflection mode. The mass (m/z ratio) of each fragment was calculated by comparing the experimental data to molecular weight standards that were used for calibration as recommended by the manufacturer.
HK Binding Assays
The wells of a 96 well microtiter plate (Maxisorb; Nunc, Wiesbaden, Germany) were coated overnight at 4°C with 100 µl of 10 µg/ml HK in coating buffer (35 mM NaHCO 3 , 15 mM NaCl, pH 9.6), blocked with 2% BSA overnight at 4°C, and incubated for 1 h at 37°C with 100 µl of a geometrical dilution series of the protein of interest (1 -0,156 µg/ml). After washing 4 times with HBS + 0.1% Triton X-100 the bound ligands were fixed by incubation with 2% formaldehyde for 20 min at room temperature and were detected by subsequent addition of anti-PHBSP or anti-PK primary and POD-labeled secondary antibodies. The development of the substrate 3,3',5,5'-tetramethylbenzidine (Sigma, Deisenhofen) proceeded for 30 min and the absorption at 450 nm was determined in an ELISA reader (SLT, Offenburg, Germany).
Cleavage of Kininogen in Human Plasma
Undiluted citrated pool plasma was incubated for 90 min at room temperature with 1/10 vol of a dilution series of PHBSP (final concentration: 4 µM-31.25 nM). The reaction was stopped by adding 90 µl of gel loading buffer including ß-mercaptoethanol and boiling for 10 minutes. Samples were loaded on a 5 -20% gel for SDS-PAGE. After protein transfer to a PVDF membrane, HK or BK were visualized by immunodetection. Additionally, the identity of the free kinin was determined by MALDI-TOF mass spectrometry. Alternatively, in a time course experiment plasma was treated with 3 µM PHBSP in the presence of 1 µM soybean trypsin inhibitor (Roche Pharmaceuticals, Mannheim, Germany) to supress potential PK activity and 10 mM captopril (Sigma) to prevent bradykinin metabolisation by angiotensin converting enzyme (ACE). At various time points (0 -240 min) samples were withdrawn and analysed by western analysis, radioimmunoassay, and MALDI-TOF mass spectrometry as described above.
